Scientists are focusing on how body weight can impact health outcomes as the obesity epidemic in the United States spreads. AYAs with acute lymphoblastic leukemia (ALL) may have worse treatment outcomes when their body mass index (BMI) is higher, according to recent research highlighted in Blood Advances.
This study clarified how weight affects treatment side effects and results and urges more research into how weight affects how well various ALL chemotherapy regimens work. By 2020, 40 per cent of the population in the United States will be obese, making it a growing public health problem. The results of the study imply that obesity, as indicated by an elevated BMI, may have a negative impact on how well AYAs respond to ALL therapy regimens.
“We have known for roughly fifteen years that obesity affects survival in pediatric patients treated for ALL, and more recently, we are recognizing a similar relationship in adult populations,” explained Shai Shimony, MD, an advanced fellow at the Dana-Farber Cancer Institute and the corresponding study’s lead author. “But we wanted more granular data on this, to understand why this correlation exists, and how dependent it is on age.”
Investigators collected data from 388 AYAs aged 15-50 years, with a mean age of 24 years, who were being treated on Dana-Farber Consortium pediatric regimens for ALL from 2008 to 2021. The researchers examined the relationship between BMI, age, toxicities, and treatment outcomes in the cohort, aiming to identify any correlations or trends.
In total, 53.3per cent of AYAs included in the study had a normal BMI, while 46.6per cent were classified as overweight or obese. Notably, patients with an overweight or obese BMI exhibited a higher rate of non-relapse mortality (11.7per cent versus 2.8per cent) a lower event-free survival rate (63per cent versus 77per cent at 4 years), and a worse overall survival (64per cent versus 83per cent) compared to those with normal BMIs. It is important to note that the study found equivalent overall survival among younger (15-29) and older (30-50) AYAs with normal BMI (83per cent versus 85per cent, respectively), which is an incredibly important finding, as age is often considered an adverse prognostic feature in ALL.
Interestingly, researchers found that the main factor driving worse outcomes among the entire cohort was non-relapse mortality, rather than disease relapse. Regarding toxicity, elevated liver enzymes and glucose levels were more frequent in patients who were considered overweight or obese (60.7per cent vs 42.2per cent, and 36.4per cent vs 24.4per cent respectively).
In the multivariable model for survival, higher BMI was associated with worse survival, while age was not associated with survival, and elevated triglycerides (fats in the bloodstream) were associated with improved survival. Elevated triglycerides reflect the activity of one of the principal chemotherapy medications (asparaginase) included in the regimen, and this finding suggests the possible use of this affordable lab test as a biomarker of treatment efficacy. However, the researchers note that this should not be viewed as an adverse finding.
“This study highlights the association between elevated BMI and increased treatment-related toxicity, non-relapse mortality, and decreased overall survival in AYAs undergoing treatment for ALL with intensive pediatric regimens,” noted Dr Shimony. Study authors Drs. Daniel DeAngelo and Marlise Luskin also highlight the effectiveness of the DFCI regimen in patients 18-50 years of age with normal BMI.
It is important to acknowledge the limitations of this study, including its retrospective nature, the absence of data on measurable residual disease outcomes, and the mostly white population. Additionally, the investigators stress that BMI, as well as other measures of obesity such as waist circumference, and waist-to-hip ratio, should be prospectively collected and correlated with outcomes in multiple treatment contexts, including patients of all ages and in the context of new regimens that incorporate novel therapies.
“Moving forward, we hope that measures of obesity will be considered a vital variable in determining the most suitable treatment regimens for each individual patient,” emphasized Dr Shimony.
(with inputs from ANI)
